https://www.fool.com/investing/2022/07/15/novavaxs-vaccine-won-us-authorization-5-reasons-wh
..
..
..
..
..
..
Novavax (NVAX) Down as EU Adds Side Effects to COVID Jab Label
https://finance.yahoo.com/news/novavax-nvax-down-eu-adds-122812455.html
Shares of Novavax NVAX fell 26.2% on Jul 14, after the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (“PRAC”) updated the product label of Nuvaxovid, the company’s COVID-19 vaccine, to include some potential side effects like severe allergic reactions and skin problems.
Per the safety report, as of Jun 26, 2022, about 216,000 doses of Nuvaxovid have been administered in the European Union, ever since the company secured approval in the region, last December.
Shares of Novavax have plunged 63.9% so far this year compared with the industry’s 20.6% decline.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM